EIDX News and Press, Eidos Therapeutics Inc. From 02/26/20

SAN FRANCISCO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on the company’s recent achievements. “2019 marked ...

Hutchison China MediTech (NASDAQ: HCM ) initiated with Buy rating and $38 (38% upside) price target at Goldman Sachs. More news on: Hutchison China MediTech Limited, Eidos Therapeutics, Inc., Intra-Cellular Therapies, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Neoleukin  Therapeutics (NASDAQ: NLTX ) initiated with Buy rating and $20 (82% upside) price target at Guggenheim. More news on: Xeris Pharmaceuticals, Inc., Neoleukin Therapeutics, Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...

Welcome to the last edition of Insider Weekends for 2019. This has been an interesting year when it comes to insider purchases, with several well-timed purchases by insiders, including: The purchase of Eidos Therapeutics ( EIDX ) by its CEO in June and then again in July . The purchas...

Biotech, hands down, wins the race for out-performance in the healthcare sector. Delivering new, valuable medicines has proven to be a winning strategy, even if the growth in their stocks is based on the hope of future drugs. However, this list focuses on the top 10 healthcare stocks in 2019, n...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 11/13/2019. Please visit our Tracking Ole Andreas Halvorsen&#...

The Netflix Prize The Netflix Prize was a competition begun in 2006 to predict user ratings for films. Competitors were given ratings scrubbed of information about the users and were challenged to find, using machine-learning methods, an algorithm based only on the raw data. Netflix provid...

Pfizer (NYSE: PFE) is out to an early lead with Vyndaqel, a drug that treats cardiomyopathy caused by transthyretin (TTR)-mediated amyloidosis (ATTR-CM), in which the TTR protein aggregates in the heart and ultimately interferes with its function. During the third quarter, the drug's first f...

With Alnylam Pharmaceuticals ( ALNY ) shares up almost 30% since my last update on the company, I can’t complain that the Street is undervaluing this RNAi pioneer nearly as much as before. Still, the company continues to build a strong investment case with two approvals in hand, ano...

Eidos Therapeutics ( EIDX +13% ) announces positive data from the ongoing open-label extension (OLE) of a Phase 2 study evaluating AG10 in patients with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM). The results were presented at the American Heart Association ...